OXULAR LIMITED

The Retinal Gene Therapy Market is projected to exceed $110 million in 2024, driven by the increasing prevalence of inherited retinal diseases, clinical trial successes, and advancements in gene therapy technologies. Despite growth, high costs and limited treatment reach pose challenges. The market is expected to evolve significantly by 2034, with opportunities in diversification, combination therapies, and precision medicine.

Calluna Pharma appoints Mark Gaffney as CEO and Mark Altmeyer as Chair of the Board. Gaffney brings 20+ years of biotech experience, previously at Oxular and Vedere Bio. Altmeyer, with extensive pharma and biotech leadership, currently chairs AM-Pharma and serves on several boards. Calluna's lead candidate, CAL101, is on track to complete Phase 1 this year.

Calluna Pharma appoints Mark Gaffney as CEO; Gaffney brings 20+ years of experience in biotech, previously CEO of Oxular Limited and COO at Vedere Bio (acquired by Novartis). Gaffney will lead Calluna's strategy as CAL101 completes Phase 1 this year.

The global Retinal Gene Therapy market, valued at US$119.15 million in 2024, is projected to grow at a CAGR of 9.6% through 2034. Driven by advancements in gene therapy technologies and clinical successes, it offers hope for treating inherited retinal diseases like retinitis pigmentosa and Leber congenital amaurosis. Key players include Novartis AG and Spark Therapeutics, with recent developments focusing on expanding treatment options and manufacturing capabilities.

The global Retinal Gene Therapy market, valued at US$119.15 million in 2024, is projected to grow at a CAGR of 9.6% through 2034. Driven by advancements in gene therapy technologies and clinical successes, it offers hope for treating inherited retinal diseases. Opportunities include diversifying targeted diseases and leveraging gene editing technologies like CRISPR-Cas9. Major players include Novartis AG and Spark Therapeutics, with recent developments highlighting strategic collaborations and manufacturing expansions.